CD16 was good to go, but they decided to get more
Post# of 148182
(Total Views: 565)
Posted On: 03/22/2021 5:10:31 PM
CD16 was good to go, but they decided to get more specific and split into:
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼